Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Gabriele Frausini"'
Autor:
Massimo Mattioli, Devis Benfaremo, Francesca Fulgenzi, Silvia Gennarini, Luciano Mucci, Flavia Giorgino, Gabriele Frausini, Gianluca Moroncini, Umberto Gnudi
Publikováno v:
Clinical and Experimental Emergency Medicine, Vol 9, Iss 1, Pp 10-17 (2022)
Objective The national health systems are currently facing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We assessed the efficacy of outpatient management for patients with SARS-CoV-2 related pneumonia at risk of progress
Externí odkaz:
https://doaj.org/article/aa104a7bb894429f9fe2da60d26d1673
Autor:
Pietro Sodani, Luciano Mucci, Rita Girolimetti, Silvia Tedesco, Francesca Monaco, Daniele Campanozzi, Marino Brunori, Stefania Maltoni, Samuele Bedetta, Anna M. Di Carlo, Piero Candoli, Mauro Mancini, Alberto Rebonato, Francesca D'Adamo, Maria Capalbo, Gabriele Frausini
Publikováno v:
Respiratory Medicine Case Reports, Vol 31, Iss , Pp 101115- (2020)
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 p
Externí odkaz:
https://doaj.org/article/196d6ddb9dce4ef4b3d8f20da3b07689
Autor:
Maria Capalbo, Manlio Pandolfini, Gino Latini, Luca D'Ascanio, Cristina Cingolani, Arianna Di Stadio, Gabriele Frausini, Paolo Gradoni, Massimo Maranzano, Michael Brenner
Publikováno v:
Otolaryngology–Head and Neck Surgery. 164:82-86
While olfactory dysfunction associated with coronavirus disease 2019 (COVID-19) has attracted considerable interest, few studies have tracked outcomes at serial time points or beyond 2 weeks. Furthermore, data are conflicting regarding whether COVID-
Autor:
Massimo Mattioli, Devis Benfaremo, Francesca Fulgenzi, Silvia Gennarini, Luciano Mucci, Flavia Giorgino, Gabriele Frausini, Gianluca Moroncini, Umberto Gnudi
Publikováno v:
Clinical and experimental emergency medicine. 9(1)
Objective The national health systems are currently facing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We assessed the efficacy of outpatient management for patients with SARS-CoV-2 related pneumonia at risk of progress
Autor:
Margherita Lambertini, Edoardo Berselli, Francesca Padiglione, Flavia Giorgino, Devis Benfaremo, Umberto Gnudi, Gabriele Frausini, Maria Capalbo, Ramona Brugnera, Silvia Gennarini, Luciano Mucci, Francesca Fulgenzi, Barbara Gabrielli, Massimo Mattioli, Gianluca Moroncini
Background Health National Systems world-wide are facing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We purpose an outpatient management for patients affected by SARS-CoV-2 related pneumonia at risk of progression, afte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cc7b631510971d5e6e1c32d95f8d805
https://doi.org/10.21203/rs.3.rs-289317/v1
https://doi.org/10.21203/rs.3.rs-289317/v1
Autor:
Fabrizio Cantini, Massimo Edoardo Di Natale, Paolo Stobbione, Assunta Navarra, Carlotta Nannini, Laura Niccoli, Gabriele Frausini, Giancarlo Landini, Massimo Di Pietro, Barbara Cimolato, Michele Trezzi, Pamela Lotti, Emanuele Nicastri, Giovanni Sotgiu, Daniela Matarrese, Delia Goletti, D. Aquilini
Publikováno v:
Journal of Infection
• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. •
Autor:
Patrizia Maria Baldini, Paola Mainquà, Alessandro Caraffa, Donatella Dennetta, Francesca Fulgenzi, M. Mancini, Antonio Polenta, Lorenzo Gasperoni, Gabriele Frausini, Massimo Mattioli, Luciano Mucci, Samuele Bedetta, Devis Benfaremo
Publikováno v:
Journal of Thrombosis and Thrombolysis
Coagulopathy represents one of the most important determinants of morbidity and mortality in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or higher doses are needed, especially in severe patients, is unknown. T
Autor:
Donatella Amico, Federico Mei, Marcello Mario D’Errico, Stefano Menzo, Laura Morbidoni, Marco B. L. Rocchi, Vincenzo G Menditto, Giovanni Pomponio, Marco Moretti, Alessia Ferrarini, Aldo Salvi, Gabriele Frausini, Abele Donati, Silvia Svegliati, Armando Gabrielli, Lina Zuccatosta, Marcello Tavio, Andrea Giacometti, Giancarlo Titolo, Maicol Onesta, Marianna Pavani, Martina Bonifazi
Background: Multiple studies have been conducted to investigate Tocilizumab in patients with cOVID-19 pneumonitis. However, published reports show conflicting results, largely due to weak retrospective designs and heterogeneity in critical methodolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c81cdb40468948129ae2b8196d8ca9f
https://doi.org/10.21203/rs.3.rs-42117/v1
https://doi.org/10.21203/rs.3.rs-42117/v1
Autor:
Piero Candoli, M. Mancini, Francesca D'Adamo, Maria Capalbo, Alberto Rebonato, Stefania Maltoni, Marino Brunori, Rita Girolimetti, Pietro Sodani, Francesca Monaco, Luciano Mucci, Samuele Bedetta, Silvia Tedesco, Gabriele Frausini, Anna Maria Di Carlo, Daniele Campanozzi
Publikováno v:
Respiratory Medicine Case Reports, Vol 31, Iss, Pp 101115-(2020)
Respiratory Medicine Case Reports
Respiratory medicine case reports, 31:101115
Respiratory Medicine Case Reports
Respiratory medicine case reports, 31:101115
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 p
Autor:
Walter Ageno, Marco Moia, Paolo Prandoni, Luigi Ria, Elvira Grandone, Cecilia Becattini, Sabine Eichinger, Renzo Poggio, Nello Zanatta, Gianluigi Scannapieco, Egidio De Gaudenzi, Mauro Silingardi, Giancarlo Agnelli, Eugenio Bucherini, Giuseppe Camporese, Aldo Salvi, Rosamaria Salvi, Roberto Cappelli, Daniela Poli, Maria Rita Vandelli, Giovanni Barillari, Sergio Siragusa, Marina Bianchi, Gabriele Frausini, Claudio Cimminiello, Carlo Bova, Roberto M. Santi, Giovanni Di Minno
Publikováno v:
ResearcherID
Abstract 543 Background A recurrence occurs in 15–20% of patients with unprovoked venous thromboembolism (VTE) in the two years after the withdrawal of oral anticoagulant treatment. Extending anticoagulant treatment is effective but associated with